Provided by Tiger Trade Technology Pte. Ltd.

Nuveen Enhanced AMT-Free Municipal Credit Opportunities Fund

11.46
-0.0960-0.83%
Volume:827.19K
Turnover:9.49M
Market Cap:2.49B
PE:4.41
High:11.55
Open:11.55
Low:11.44
Close:11.56
52wk High:13.59
52wk Low:11.27
Shares:216.79M
Float Shares:216.79M
Volume Ratio:1.07
T/O Rate:0.38%
Dividend:0.95
Dividend Rate:8.27%
EPS(TTM):2.60
EPS(LYR):0.2671
ROE:2.01%
ROA:2.37%
PB:0.90
PE(LYR):42.92

Loading ...

Nuveen AMT-Free Municipal Credit Income Fund Portfolio Manager Kristen Dejong Files Initial Beneficial Ownership Statement

Reuters
·
Sep 04

Nuveen AMT-Free Municipal Credit Income Fund Vice President Parth Doshi Files Initial Beneficial Ownership Statement

Reuters
·
Aug 29

Nuveen AMT-Free Municipal Credit Income Fund Portfolio Manager Paul L. Brennan Sells 5,000 Common Shares Worth $62,240

Reuters
·
Aug 13

Nuveen Amt-free Municipal Credit Income Fund Announces Annual Shareholder Meeting

Reuters
·
Jul 02

Recent Dividend Declarations

Dow Jones
·
Jun 04

NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3

TIPRANKS
·
May 27

NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291

TIPRANKS
·
May 26

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

GlobeNewswire
·
May 26

NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development

TIPRANKS
·
May 23

NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows

TIPRANKS
·
May 19

Press Release: Vision Marine Technologies Accelerates Operational Transformation with NVG Segment Near EBITDA Breakeven and Significant Balance Sheet Improvements

Dow Jones
·
Apr 15

NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury

TIPRANKS
·
Apr 02

NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions

TIPRANKS
·
Apr 01